Advanced search

Filters

Country

All countries

North America

South America

Europe

Africa

Middle East

Asia

Oceania

Central America

Select all

Capitalization

Sector

All sectors

  Energy

  Basic Materials

  Industrials

  Consumer Cyclicals

  Consumer Non-Cyclicals

  Financials

  Healthcare

  Technology

  Utilities

  Real Estate

  Institutions, Associations & Organizations

  Government Activity

  Academic & Educational Services

Select all

Add a keyword

Announcement Date

Since

Until

146 Results

Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors
BU
Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
BU
Mirati Therapeutics, Inc. Announces Management Changes
CI
Transcript : Gossamer Bio, Inc. - Special Call
Gossamer Bio Appoints Bob Smith as Chief Commercial Officer
BU
Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors
BU
Gossamer Bio Announces Third Quarter 2023 Financial Results and Provides Business Update
BU
Kura Oncology : Corporate Presentation - November 2023
PU
Gossamer Bio Announces Addition of Rainer Zimmermann, MD, as VP of Medical Affairs
BU
Gossamer Bio Announces Second Quarter 2023 Financial Results and Provides Business Update
BU
Mirati Therapeutics Announces Departure of Chief Executive Officer David Meek
PR
Transcript : Gossamer Bio, Inc. - Special Call
Gossamer Bio Announces $212 Million Private Placement Financing
BU
Transcript : Gossamer Bio, Inc. Presents at Goldman Sachs 44th Annual Global Healthcare Conference, Jun-13-2023 04:40 PM
GOSSAMER BIO, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
AQ
Kura Oncology : Corporate Presentation - May 2023
PU
Gossamer Bio Announces First Quarter 2023 Financial Results and Provides Business Update
BU
Kura Oncology : Corporate Presentation - February 2023
PU
Transcript : Gossamer Bio, Inc. - Special Call
Gossamer Bio Announces Seralutinib Meets Primary Endpoint in Phase 2 TORREY Study in PAH
BU
Gossamer Bio Announces Third Quarter 2022 Financial Results and Provides Business Update
BU
Gossamer Bio : Announces Second Quarter 2022 Financial Results and Provides Business Update - Form 8-K
PU
Gossamer Bio Announces Second Quarter 2022 Financial Results and Provides Business Update
BU
Gossamer Bio : Announces $120 million Private Placement Financing - Form 8-K
PU
Gossamer Bio Announces $120 Million Private Placement Financing
BU
Gossamer Bio Announces Publication of Key Preclinical Data in the European Respiratory Journal Highlighting Seralutinib’s Potential for the Treatment of PAH
BU
MIRATI THERAPEUTICS, INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
AQ
Transcript : Gossamer Bio, Inc. Presents at Bank of America 2022 Healthcare Conference, May-11-2022 10:00 AM
Gossamer Bio Announces First Quarter 2022 Financial Results and Provides Business Update
BU
Transcript : Gossamer Bio, Inc. - Special Call
Gossamer Bio Announces GB004 Topline Results from Phase 2 SHIFT-UC Study in Ulcerative Colitis and Provides Corporate Update
BU
Transcript : Gossamer Bio, Inc., Q4 2021 Earnings Call, Mar 03, 2022
Gossamer Bio : Announces Fourth Quarter and Full-Year 2021 Financial Results and Provides Business Update - Form 8-K
PU
Gossamer Bio Announces Fourth Quarter and Full-Year 2021 Financial Results and Provides Business Update
BU
Transcript : Gossamer Bio, Inc., Q3 2021 Earnings Call, Nov 08, 2021
Kura Oncology - Corporate Presentation - November 2021
PU
Gossamer Bio Announces Addition of Two CNS-Penetrant BTK Inhibitors to its Product Candidate Pipeline: GB5121 & GB7208 - Form 8-K
PU
Transcript : Gossamer Bio, Inc. - Special Call
Gossamer Bio Announces Addition of Two CNS-Penetrant BTK Inhibitors to its Product Candidate Pipeline: GB5121 & GB7208
BU
Gossamer Bio : Announces Appointment of Bryan Giraudo as Chief Operating Officer, in addition to Chief Financial Officer Role (Form 8-K)
PU
Gossamer Bio : Announces Appointment of Bryan Giraudo as Chief Operating Officer, in addition to Chief Financial Officer Role
BU
Kura Oncology : Corporate Presentation - September 2021
PU
Transcript : Gossamer Bio, Inc., Q2 2021 Earnings Call, Aug 09, 2021
Gossamer Bio : Announces Second Quarter 2021 Financial Results and Provides Corporate Update
BU
KURA ONCOLOGY, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
Caryn Peterson Joins Aspen Neuroscience Board of Directors
PR
Gossamer Bio : Announces Promotion of Richard Aranda, M.D., to Chief Medical Officer
BU
Gossamer Bio : Announces Appointment of Sandra Milligan, M.D., J.D., to its Board of Directors (Form 8-K)
PU
Gossamer Bio : Announces Appointment of Sandra Milligan, M.D., J.D., to its Board of Directors
BU
MIRATI THERAPEUTICS, INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
AQ
No results for this search
  1. Stock Market
  2. Advanced search
  3. Faheem Hasnain
  4. News